BMJ · 2022 · 187 citations · 31 references
Veterinary MedicineInfectious DiseasesPreventive MedicineEpidemiologyImmunizationVaccinologyVaccinationVaccination PolicyVaccine EffectivenessVaccine PolicyVaccine SafetyVaccine Scale-upPopulation-based Vaccine EffectivenessPopulation-level Mortality PatternsPublic Health Impact AssessmentScale-up Of Vaccine ProductionVaccination Impact AnalysisVaccination Impact AssessmentVaccination Impact ModelingVaccine-preventable Disease Surveillance
Abstract Objective To evaluate the impact of vaccine scale-up on population level covid-19 mortality and incidence in the United States. Design Observational study. Setting US county level case surveillance and vaccine administration data reported from 14 December 2020 to 18 December 2021. Participants Residents of 2558 counties from 48 US states. Main outcome measures The primary outcome was county covid-19 mortality rates (deaths/100 000 population/county week). The secondary outcome was incidence of covid-19 (cases/100 000 population/county week). Incidence rate ratios were used to compare rates across vaccination coverage levels. The impact of a 10% improvement in county vaccination coverage (defined as at least one dose of a covid-19 vaccine among adults ≥18 years of age) was estimated During the eras of alpha and delta variant predominance, the impact of very low (0-9%), low (10-39%), medium (40-69%), and high (≥70%) vaccination coverage levels was compared. Results In total, 30 643 878 cases of covid-19 and 439 682 deaths associated with covid-19 occurred over 132 791 county weeks. A 10% improvement in vaccination coverage was associated with an 8% (95% confidence interval 8% to 9%) reduction in mortality rates and a 7% (6% to 8%) reduction in incidence. Higher vaccination coverage levels were associated with reduced mortality and incidence rates during the eras of alpha and delta variant predominance. Conclusions Higher vaccination coverage was associated with lower rates of population level covid-19 mortality and incidence in the US.
31
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Jerald Sadoff, Glenda Gray, An Vandebosch et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text